S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Latest freight railroad layoffs and Wall Street pressure renew concerns about safety and service
Critical asset just had biggest fall on record (Ad)
How major US stock indexes fared Friday, 3/1/2024
Brazil's economy grows 2.9% in Lula's 1st year, beating expectations
Critical asset just had biggest fall on record (Ad)
Question of whether Nebraska public money can go to private schools still set for November ballot
A US appeals court ruling could allow mine development on Oak Flat, land sacred to Apaches
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Peace, music and memories: As the 1960s fade, historians scramble to capture Woodstock's voices
Georgia's largest county is still repairing damage from January cyberattack
NASDAQ:CGEN

Compugen (CGEN) Stock Price, News & Analysis

$2.64
+0.06 (+2.33%)
(As of 03/1/2024 ET)
Today's Range
$2.57
$2.70
50-Day Range
$1.68
$2.65
52-Week Range
$0.53
$2.85
Volume
686,180 shs
Average Volume
520,750 shs
Market Capitalization
$228.68 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

Compugen MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
51.5% Upside
$4.00 Price Target
Short Interest
Healthy
2.42% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.16mentions of Compugen in the last 14 days
Based on 8 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.20) to ($0.04) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.94 out of 5 stars

Medical Sector

658th out of 952 stocks

Biological Products, Except Diagnostic Industry

107th out of 160 stocks


CGEN stock logo

About Compugen Stock (NASDAQ:CGEN)

Compugen Ltd., a clinical-stage therapeutic discovery and development company, researches, develops, and commercializes therapeutic and product candidates in Israel, the United States, and Europe. The company's immuno-oncology pipeline consists of COM701, an anti-PVRIG antibody that is in Phase I clinical study used for the treatment of solid tumors; COM902, a therapeutic antibody targeting TIGIT, which is in Phase I monotherapy clinical study in patients with advanced malignancies through sequential dose escalations; Bapotulimab, a therapeutic antibody targeting ILDR2 that is in Phase I clinical study in patients with naïve head and neck squamous cell carcinoma; and Rilvegostomig, a novel anti-TIGIT/PD-1 bispecific antibody, which is in Phase II clinical study in patients with advanced or metastatic non-small cell lung cancer. Its therapeutic pipeline also includes early-stage immuno-oncology programs focused to address various mechanisms of immune resistance; and COM503, high affinity antibody, which blocks the interaction between IL-18 binding protein and IL-18. The company has collaboration agreement with Bayer Pharma AG for the research, development, and commercialization of antibody-based therapeutics against the company's immune checkpoint regulators; Bristol-Myers Squibb to evaluate the safety and tolerability of COM701 in combination with Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and Johns Hopkins School of Medicine to evaluate novel T cell and myeloid checkpoint targets. It has license agreement with AstraZeneca for the development of bi-specific and multi-specific immuno-oncology antibody products; and research collaboration with Johns Hopkins University for myeloid. Compugen Ltd. was incorporated in 1993 and is headquartered in Holon, Israel.

CGEN Stock Price History

CGEN Stock News Headlines

Compugen (CGEN) Scheduled to Post Quarterly Earnings on Tuesday
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Compugen Stock (NASDAQ:CGEN), Short Interest Report
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Compugen (CGEN) is a Great Momentum Stock: Should You Buy?
CGEN Mar 2024 7.500 call
CGEN Mar 2024 1.500 put
Top 4 Biotech Stock Buys for 2024 Gains
See More Headlines
Receive CGEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Compugen and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/07/2023
Today
3/02/2024
Next Earnings (Confirmed)
3/05/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:CGEN
Employees
69
Year Founded
1993

Price Target and Rating

Average Stock Price Target
$4.00
High Stock Price Target
$4.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+51.5%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-33,690,000.00
Pretax Margin
-420.49%

Debt

Sales & Book Value

Annual Sales
$7.50 million
Book Value
$0.90 per share

Miscellaneous

Free Float
78,396,000
Market Cap
$228.68 million
Optionable
Optionable
Beta
2.66

Social Links

Elon Musk's Next Move Cover

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Key Executives

  • Dr. Anat Cohen-Dayag Ph.D. (Age 57)
    CEO, President & Director
    Comp: $796.52k
  • Dr. Zurit Levine Ph.D. (Age 56)
    Senior Vice President of Technology Innovation
    Comp: $345.7k
  • Dr. Henry Adewoye M.D. (Age 59)
    Senior VP & Chief Medical Officer
    Comp: $605.29k
  • Dr. Pierre Ferre Ph.D. (Age 47)
    Vice President of Preclinical Development
    Comp: $415.1k
  • Mr. Alberto Sessa (Age 62)
    Chief Financial Officer
  • Dr. Eran Ophir Ph.D. (Age 46)
    Chief Scientific Officer
  • Ms. Yvonne Naughton
    Head of Investor Relations & Corporate Communications
  • Mr. Eran Ben Dor
    General Counsel & Corporate Secretary
  • Ms. Dorit Amitay (Age 56)
    Vice President of Human Resources
  • Dr. Yaron Turpaz M.B.A. (Age 53)
    Ph.D., Senior VP & Senior Advisor of Data and Informatics Solutions














CGEN Stock Analysis - Frequently Asked Questions

Should I buy or sell Compugen stock right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Compugen in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" CGEN shares.
View CGEN analyst ratings
or view top-rated stocks.

What is Compugen's stock price target for 2024?

2 Wall Street analysts have issued 12-month price objectives for Compugen's stock. Their CGEN share price targets range from $4.00 to $4.00. On average, they predict the company's share price to reach $4.00 in the next year. This suggests a possible upside of 51.5% from the stock's current price.
View analysts price targets for CGEN
or view top-rated stocks among Wall Street analysts.

How have CGEN shares performed in 2024?

Compugen's stock was trading at $1.98 at the beginning of 2024. Since then, CGEN stock has increased by 33.3% and is now trading at $2.64.
View the best growth stocks for 2024 here
.

Are investors shorting Compugen?

Compugen saw a increase in short interest during the month of February. As of February 15th, there was short interest totaling 2,020,000 shares, an increase of 23.9% from the January 31st total of 1,630,000 shares. Based on an average trading volume of 2,660,000 shares, the short-interest ratio is currently 0.8 days. Currently, 2.4% of the shares of the company are short sold.
View Compugen's Short Interest
.

When is Compugen's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 5th 2024.
View our CGEN earnings forecast
.

How can I listen to Compugen's earnings call?

Compugen will be holding an earnings conference call on Tuesday, March 5th at 8:30 AM Eastern. Interested parties can register for or listen to the call using this link.

How were Compugen's earnings last quarter?

Compugen Ltd. (NASDAQ:CGEN) released its quarterly earnings data on Monday, August, 7th. The biotechnology company reported ($0.11) EPS for the quarter, beating the consensus estimate of ($0.13) by $0.02. During the same period in the previous year, the company earned ($0.11) EPS.

What is Anat Cohen-Dayag's approval rating as Compugen's CEO?

2 employees have rated Compugen Chief Executive Officer Anat Cohen-Dayag on Glassdoor.com. Anat Cohen-Dayag has an approval rating of 100% among the company's employees. This puts Anat Cohen-Dayag in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Compugen own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Compugen investors own include Oramed Pharmaceuticals (ORMP), NVIDIA (NVDA), Advanced Micro Devices (AMD), QUALCOMM (QCOM), AbbVie (ABBV), Inovio Pharmaceuticals (INO), Netflix (NFLX), Gilead Sciences (GILD) and Pfizer (PFE).

Who are Compugen's major shareholders?

Compugen's stock is owned by many different retail and institutional investors. Top institutional investors include Taylor Frigon Capital Management LLC (2.19%), Sphera Funds Management LTD. (0.89%), UBS Group AG (0.36%), Goldman Sachs Group Inc. (0.14%), Goldman Sachs Group Inc. (0.14%) and Northern Trust Corp (0.13%).

How do I buy shares of Compugen?

Shares of CGEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:CGEN) was last updated on 3/2/2024 by MarketBeat.com Staff